SAN DIEGO--(BUSINESS WIRE)--Today, Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, announced MRDVision, its solution for minimal residual disease (MRD) detection, validated to ...
According to the World Health Organization, cancer diagnoses remain a leading cause of death. However, scientific and medical communities have improved clinical outcomes for many people, transforming ...
Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...
Using the newly created MAESTRO-Pool tool, whole genome sequencing revealed DNA that could be used to more effectively detect minimum residual disease (MRD) in patients who have diffuse large B-cell ...
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out Clinical trials frequently include multiple end points that mature at different times. The initial report, ...
Circulating tumor DNA in decision-making of patients with metastatic colorectal cancer after failure of first-line treatment containing cetuximab: A single-center, phase II trial. This is an ASCO ...
MRD detection is the future — allowing us to monitor patients in real-time. The data is strong and we're excited that our approach can now be incorporated into future studies." Dr. Roy Herbst, study's ...
ctDNA detection has advanced, allowing identification of minimal residual disease and predicting cancer recurrence with high sensitivity. Liquid biopsies offer a minimally invasive method to analyze ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results